Drug Profile
Research programme: nociceptin receptor antagonists - The GI Company
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator The GI Company
- Class
- Mechanism of Action Nociceptin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Diarrhoea; Irritable bowel syndrome
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Diarrhoea in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Irritable-bowel-syndrome in USA